ESR1 and breast neoplasm: Daemen and Manning explored HER2 amplification in 3155 breast tumors and found that the HER2–enriched (HER2E) subtype had a distinct transcriptional landscape independent of HER2-amplificated (HER2A) that reflected and confirmed how AR signaling can replace ER-driven tumorigenesis (Daemen and Manning, 2018).